“DuPont is very pleased with the revocation of Novozymes’ invalid patent. The outcome provides our customers with choice and recognizes our rights in the marketplace as a true innovator. We intend to vigorously pursue all available avenues to protect our products and the market,” Soonhee Jang, vice president, IP Strategy and Chief IP Counsel, DuPont Industrial Biosciences.
